SB
Sumayya Binth Ismail
About Sumayya Binth Ismail
Data last updated:
Sumayya Binth Ismail has 8 years in corporate governance. Holds Director role. Currently with 1 company, including Southzone Hospitals And Research Centre Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Southzone Hospitals And Research Centre Private Limited at ₹6.80 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 13 Mar 2018 | 2010 | ₹6.80 Cr (FY 2024) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sumayya Binth Ismail
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sumayya Binth Ismail
Sumayya Binth Ismail has 8 years in corporate governance. Holds Director role. Currently with 1 company, including Southzone Hospitals And Research Centre Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Southzone Hospitals And Research Centre Private Limited at ₹6.80 Cr (FY 2024).
Sumayya Binth Ismail is associated with 1 company as Director, including Southzone Hospitals And Research Centre Private Limited (₹6.80 Cr).
Sumayya Binth Ismail has expertise in General Business.
Sumayya Binth Ismail has 8 years in corporate governance.
By reported revenue, the largest current company of Sumayya Binth Ismail is Southzone Hospitals And Research Centre Private Limited, with revenue of ₹6.80 Cr (FY 2024).
Sumayya Binth Ismail currently holds positions at 1 company: Southzone Hospitals And Research Centre Private Limited (₹6.80 Cr).